论文部分内容阅读
目的观察西他列汀联合格列齐特治疗老年2型糖尿病的临床疗效。方法设定2009年5月—2011年5月为观察时间,选104例老年2型糖尿病患者为观察对象,随机分为观察组及对照组,每组52例,对照组给于格列齐特治疗,观察组给予西他列汀联合格列齐特治疗,观察两组疗效及安全性。结果 2组治疗后HbA1c、FPG、2hPG水平均显著下降(P<0.05),且观察组下降程度优于对照组(P<0.05);2组均未出现严重不良反应,观察组低血糖发生率显著低于对照组(P<0.05)。结论西他列汀联合格列齐特治疗老年2型糖尿病疗效显著,不良反应少,值得临床上推广应用。
Objective To observe the clinical efficacy of sitagliptin and gliclazide in the treatment of type 2 diabetes in the elderly. Methods To set the observation time from May 2009 to May 2011, 104 elderly patients with type 2 diabetes mellitus were randomly divided into observation group and control group, with 52 cases in each group. The control group was given gliclazide The treatment group and the observation group were treated with sitagliptin and gliclazide. The curative effect and safety of the two groups were observed. Results The levels of HbA1c, FPG and 2hPG in the two groups were significantly decreased (P <0.05), and the degree of decline in the observation group was better than that in the control group (P <0.05). No serious adverse reactions were observed in the two groups. The incidence of hypoglycemia Significantly lower than the control group (P <0.05). Conclusion Sitagliptin combined with gliclazide in the treatment of elderly type 2 diabetes has obvious curative effect and few adverse reactions, which is worth popularizing and clinical application.